Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings
Abstract
1. Introduction
2. Clobenzorex
3. Fenproporex
4. Triiodothyronine
5. Amfepramone
6. Final Considerations
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Zhang, Y.; Liu, J.; Yao, J.; Ji, G.; Qian, L.; Wang, J.; Zhang, G.; Tian, J.; Nie, Y.; Gold, M.; et al. Obesity: Pathophysiology and Intervention. Nutrients 2014, 6, 5153–5183. [Google Scholar] [CrossRef] [PubMed]
- López-Canales, J.; Lozano-Cuenca, J.; Morín-Zaragoza, R.; Rodríguez-Almaraz, J.; López-Canales, O. Posible mecanismo involucrado en el efecto vasodilatador inducido por fenproporex en anillos aórticos de rata. Rev. Hosp. Juárez Mex. Oct. 2013, 80, 235–242. [Google Scholar]
- Apovian, C.M.; Aronne, L.J.; Bessesen, D.H.; McDonnell, M.E.; Murad, M.H.; Pagotto, U.; Ryan, D.H.; Still, C.D. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2015, 100, 2135–2136. [Google Scholar] [CrossRef] [PubMed]
- Kushner, R. Weight Loss Strategies for Treatment of Obesity. Prog. Cardiovasc. Dis. 2014, 56, 465–472. [Google Scholar] [CrossRef] [PubMed]
- Rivera, G.; De la Garza, M.; Flores, G.; Acosta, R.; Bocanegra, A. Treatment of the obesity; new perspective. Rev. Mex. Cienc. Farm. 2008, 38, 48–56. [Google Scholar]
- Aronson, J. Side Effects of Drugs Annual, 16th ed.; Elsevier Science Ltd.: Oxford, UK, 2016. [Google Scholar]
- Caixas, A. Pharmacological treatment of obesity. Endocrinol. Nutr. 2000, 47, 16. [Google Scholar]
- Galicia, M.; Simal, A. Tratamiento farmacológico de la obesidad. Inf. Ter. Sist. Nac. Salud 2002, 26, 117–120. [Google Scholar]
- Hampp, C.; Kang, E.; Borders-Hemphill, V. Use of Prescription Antiobesity Drugs in the United States. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2013, 33, 1299–1307. [Google Scholar] [CrossRef] [PubMed]
- Hendricks, E.J.; Srisurapanont, M.; Schmidt, S.L.; Haggard, M.; Souter, S.; Mitchell, C.L.; De Marco, D.G.; Hendricks, M.J.; Istratiy, Y.; Greenway, F.L. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int. J. Obes. 2013, 38, 292–298. [Google Scholar] [CrossRef] [PubMed]
- Mariotti, K.C.; Rossato, L.G.; Fröehlich, P.E.; Limberger, R.P. Amphetamine-type medicines: A review of pharmacokinetics, pharmacodynamics, and toxicological aspects. Curr. Clin. Pharmacol. 2013, 8, 350–357. [Google Scholar] [CrossRef] [PubMed]
- Cheung, B.; Tsang, T.; Rajitha, N. Safety of antiobesity drugs. Ther. Adv. Drug Saf. 2013, 4, 171–181. [Google Scholar] [CrossRef] [PubMed]
- Kang, J.G.; Park, C.-Y. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab. J. 2012, 36, 13–25. [Google Scholar] [CrossRef] [PubMed]
- Saunders, K.; Umashanker, D.; Igel, L.; Kumar, R.; Aronne, L. Obesity Pharmacotherapy. Med. Clin. N. Am. 2018, 102, 135–148. [Google Scholar] [CrossRef] [PubMed]
- Yanovski, S.; Yanovski, J. Long-term Drug Treatment for Obesity. JAMA 2014, 311, 74. [Google Scholar] [CrossRef] [PubMed]
- Valtier, S.; Cody, J.T. Metabolic production of amphetamine following administration of clobenzorex. J. Forensic Sci. 1999, 44, 17–22. [Google Scholar] [CrossRef] [PubMed]
- Lozano-Cuenca, J.; González-Hernández, A.; López-Canales, O.A.; Villagrana-Zesati, J.R.; Rodríguez-Choreño, J.D.; Morín-Zaragoza, R.; Castillo-Henkel, E.F.; López-Canales, J.S. Possible mechanisms involved in the vasorelaxant effect produced by clobenzorex in aortic segments of rats. Braz. J. Med. Biol. Res. 2017, 50. [Google Scholar] [CrossRef] [PubMed]
- Seferian, A.; Chaumais, M.C.; Savake, L.; Gunther, S.; Tubert-Bitter, P.; Humbert, M. Drug induced pulmonary arterial hypertension. Presse Med. 2013, 42 Pt 2, e303–e310. [Google Scholar] [CrossRef]
- Espinosa-Franco, B.; Morín-Zaragoza, R. Efectos adversos de fármacos anorexigénicos de liberación prolongada. Rev. Esp. Cienc. Salud 2013, 16, 32–40. [Google Scholar]
- Kraemer, T.; Pflugmann, T.; Bossmann, M.; Kneller, N.M.; Peters, F.T.; Paul, L.D.; Springer, D.; Staack, R.F.; Maurer, H.H. Fenproporex N-dealkylation to amphetamine—Enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochem. Pharmacol. 2004, 68, 947–957. [Google Scholar] [CrossRef] [PubMed]
- Paumgartten, F.; Pereira, S.; Oliveira, A. Safety and efficacy of fenproporex for obesity treatment: A systematic review. Rev. Saúde Públ. 2016, 50, 25. [Google Scholar] [CrossRef] [PubMed]
- Behar, R. Anorexigens: Indications and Interactions. Rev. Chil. Neuropsiquiatr. 2002, 40, 21–36. [Google Scholar]
- Lucchetta, R.C.; Riveros, B.S.; Pontarolo, R.; Radominski, R.B.; Otuki, M.F.; Fernandez-Llimos, F.; Correr, C.J. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics 2017, 72, 317–324. [Google Scholar] [CrossRef]
- Zolkowska, D.; Rothman, R.B.; Baumann, M.H. Amphetamine analogs increase plasma serotonin: Implications for cardiac and pulmonary disease. J. Pharmacol. Exp. Ther. 2006, 318, 604–610. [Google Scholar] [CrossRef] [PubMed]
- Kaptein, E.; Beale, E.; Chan, L. Thyroid Hormone Therapy for Obesity and Nonthyroidal Illnesses: A Systematic Review. J. Clin. Endocrinol. Metab. 2009, 94, 3663–3675. [Google Scholar] [CrossRef] [PubMed]
- Biondi, B.; Palmieri, E.A.; Lombardi, G.; Fazio, S. Subclinical hypothyroidism and cardiac function. Thyroid Off. J. Am. Thyroid Assoc. 2002, 12, 505–510. [Google Scholar] [CrossRef] [PubMed]
- Lozano-Cuenca, J.; Lopez-Canales, O.A.; Aguilar-Carrasco, J.C.; Villagrana-Zesati, J.R.; Lopez-Mayorga, R.M.; Castillo-Henkel, E.F.; López-Canales, J.S. Pharmacological study of the mechanisms involved in the vasodilator effect produced by acute application of triiodothyronine to rat aortic rings. Braz. J. Med. Biol. Res. 2016, 49, e5304. [Google Scholar] [CrossRef] [PubMed]
- Tang, M.H.; Chen, S.P.; Ng, S.W.; Chan, A.Y.; Mak, T.W. Case series on a diversity of illicit weight-reducing agents: From the well-known to the unexpected. Br. J. Clin. Pharmacol. 2011, 71, 250–253. [Google Scholar] [CrossRef] [PubMed]
- Pearce, E. Thyroid Hormone and Obesity. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19, 408–413. [Google Scholar] [CrossRef] [PubMed]
- Álvarez-Castro, P.; Sangiao-Alvarellos, S.; Brandón-Sandá, I.; Cordido, F. Función endócrina en la obesidad. Endocrinol. Nutr. 2011, 58, 422–432. [Google Scholar] [CrossRef] [PubMed]
- López-Canales, J.S.; Lozano-Cuenca, J.; Muãoz-Islas, E.; Aguilar-Carrasco, J.C.; López-Canales, O.A.; Lopez-Mayorga, R.M.; Castillo-Henkel, E.F.; Valencia-Hernández, I.; Castillo-Henkel, C. Mechanisms involved in the vasorelaxant effects produced by the acute application of amfepramone in vitro to rat aortic rings. Braz. J. Med. Biol. Res. 2015, 48, 537–544. [Google Scholar] [CrossRef] [PubMed]
- Soto Molina, H.; Pizarro Castellanos, M.; Rosado Pérez, J.; Rizzoli Córdoba, A. Six-month efficacy and safety of amfepramone in obese Mexican patients: A double-blinded, randomized, controlled trial. Int. J. Clin. Pharmacol. Ther. 2015, 53, 541–549. [Google Scholar] [CrossRef] [PubMed]
- Fradet, E.; Buxeraud, J. Les anorexigènes centraux: Revue générale dans la prise en charge des obésités majeures. Lyon Pharm. 1999, 50, 2. [Google Scholar]
- Safta, L.; Cuparencu, B. Cardiovascular effects of amphepramone. Physiologie 1978, 15, 117–125. [Google Scholar] [PubMed]
- Abdallah, A.H.; Roby, D.M. Effect of (3′,4′-dichloro-2(2-imidazolin-2-yl-thio)-acetophenone hydrobromide) (DITA) on pulmonary and systemic arterial blood pressure: A comparison with diethylpropion. J. Pharm. Pharmacol. 1977, 29, 318–319. [Google Scholar] [CrossRef] [PubMed]
- Crols, R.; Dierckx, R.; Saerens, J.; De Deyn, P.P. Transient ischemic attacks associated with amfepramone therapy: A case report. Funct. Neurol. 1993, 8, 351–354. [Google Scholar] [PubMed]
- Li, M.F.; Cheung, B.M. Rise and Fall of Anti-Obesity Drugs. World J. Diabetes 2011, 2, 19–23. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
García-Alonso, D.; Morgenstern-Kaplan, D.; Cohen-Welch, A.; Lozano-Cuenca, J.; López-Canales, J.S. Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings. Med. Sci. 2019, 7, 39. https://doi.org/10.3390/medsci7030039
García-Alonso D, Morgenstern-Kaplan D, Cohen-Welch A, Lozano-Cuenca J, López-Canales JS. Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings. Medical Sciences. 2019; 7(3):39. https://doi.org/10.3390/medsci7030039
Chicago/Turabian StyleGarcía-Alonso, Daniela, Dan Morgenstern-Kaplan, Ariel Cohen-Welch, Jair Lozano-Cuenca, and Jorge Skiold López-Canales. 2019. "Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings" Medical Sciences 7, no. 3: 39. https://doi.org/10.3390/medsci7030039
APA StyleGarcía-Alonso, D., Morgenstern-Kaplan, D., Cohen-Welch, A., Lozano-Cuenca, J., & López-Canales, J. S. (2019). Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings. Medical Sciences, 7(3), 39. https://doi.org/10.3390/medsci7030039